Report library

MedTech analysis
Special bundles
Strategy analysis
Strategy analysis
Disease analysis
Company analysis
Drug analysis
MedTech analysis

Text search

Sort by Random

Display 15 Products per page

Ophthalmic Surgical Products Market

$4,750.00

At $9.1bn, the ophthalmic surgical products market is one of the largest medical device markets globally, and serves an important need: preventing blindness for millions of people who suffer from cataracts, glaucoma, vitreoretinal disease, and refractive errors.
December 8, 2021
Find out more
Orthobiologics for Musculoskeletal Soft Tissue Replacement and Regeneration – 2021

$4,750.00

This medical market and technology report provides a comprehensive discussion of the global market for orthobiologics for musculoskeletal soft tissue replacement and regeneration. Geographic markets covered by this analysis comprise the US, Japan, five major European markets (France, Germany, Italy, Spain, and the UK), and the rest of world (RoW), which includes all other countries.
November 2, 2021
Find out more
Rheumatoid Arthritis Payer Interview – Pennsylvania, US

$599.00

A US payer provides insights into pricing and reimbursement dynamics and issues surrounding biosimilars, key marketed brands, and late-phase pipeline therapies for rheumatoid arthritis.
August 22, 2019
Find out more
Market Spotlight: Thyroid Cancer

$1,318.00

This Market Spotlight report covers the Thyroid Cancer market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, regulatory events, probability of success, a 10-year disease incidence and five-year prevalence forecast, and licensing and asset acquisition deals, as well as presenting drug-specific revenue forecasts.
April 7, 2022
Find out more
Pacts in Medtech

$199.00

Pacts in Medtech – September/October 2016 – notable technology alliances, R&D partnerships and commercial collaborations disclosed in July and August 2016.
November 18, 2016
Find out more
Datamonitor Healthcare HR+/HER2- Breast Cancer KOL Interview – UK

$599.00

A UK key opinion leader (KOL) provides insight into the current and future treatment dynamics of HR+/HER2- breast cancer, as well as critical unmet needs in the treatment space.
January 8, 2019
Find out more
Disease Analysis: Chronic Myeloid Leukemia (CML)
Read More
Chronic myeloid leukemia (CML) is defined as a cancer of the blood in which a mutation in myeloid hematopoietic stem cells causes the overproduction of immature and dysfunctional white blood cells (myeloblasts, also known as blasts), preventing the normal production and function of healthy white blood cells, red blood cells, and platelets.
February 25, 2022
Find out more
Viibryd
Read More
Viibryd (vilazodone; Allergan) belongs to a new class of antidepressants, combining selective serotonin reuptake inhibitor activity with partial 5-HT1A receptor agonism, in order to produce its therapeutic effect.
March 29, 2019
Find out more
Menveo
Read More
Menveo (quadrivalent oligosaccharide diphtheria CRM-197 conjugate vaccine; GlaxoSmithKline) is a quadrivalent meningococcal glycoconjugate vaccine that uses CRM-197, a natural mutant of the diphtheria toxin, as well as an aluminum phosphate adjuvant. It is approved for the prevention of meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y, and W-135 in individuals aged two months to 55 years in both the US and EU.
September 3, 2019
Find out more
Seroquel/Seroquel XR
Read More
The Seroquel franchise contains quetiapine, which acts as an antagonist at multiple neurotransmitter receptors in the brain, such as serotonin 5-HT1A and 5-HT2, dopamine D1 and D2, histamine H1, and adrenergic alpha 1 and alpha 2 receptors.
March 29, 2019
Find out more
Disease Analysis: Depression
Read More
While it is not uncommon to experience feelings of sadness occasionally, in most people these emotions are usually fleeting and pass after a few days. When this manifests in a depressive disorder, a patient’s symptoms interfere with daily life and normal functioning. Depression is the leading cause of disability globally and can cause a multitude of symptoms, many of which are associated with impairment and, ultimately, decreased productivity
April 8, 2022
Find out more
Spinal Fusion: Implanted Instrumentation

$4,750.00

Sales of implanted instrumentation for spinal fusion procedures totaled approximately $4.4bn in 2019, with sales expected to climb at a CAGR of 2.2% through 2024. Growth in the spinal fusion instrumentation market is being driven by several factors including the prevalence of degenerative disc disease, new surgical techniques and associated instrumentation that have expanded the range of product indications, and the launch of new enabling technology such as diagnostic, nerve monitoring, and navigation systems (including robotic-assisted surgery).
August 20, 2020
Find out more
Xarelto
Read More
Xarelto (rivaroxaban; Bayer/Johnson & Johnson) is an oral anticoagulant indicated for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) in the US, EU, and Japan.
March 15, 2018
Find out more
Latuda
Read More
Latuda (lurasidone; Sumitomo Dainippon/Angelini) contains the atypical antipsychotic lurasidone, which acts as an antagonist of dopamine receptors D2, and serotonin receptors 5-HT2A. By inhibiting the synaptic reuptake of dopamine and serotonin, Latuda helps to normalize brain activity and reduce schizophrenia symptoms.
March 29, 2019
Find out more
Mirogabalin
Read More
Mirogabalin (Daiichi Sankyo) is an oral therapy that preferentially and selectively binds to the α2δ-1 (alpha-2 delta-1) subunit of calcium channels widely found in the nervous system in areas that mediate pain transmission and processing.
May 31, 2018
Find out more

Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!

Pharma Intelligence

This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Call Back

Name

Email *

Company name *

Phone number *